Regulatory Approval

All Clinical Trial Regulatory Merger & Acquisitions Blogs

12 May 2025

InnoCare's Mesutoclax Receives Breakthrough Therapy Designation in China

InnoCare Pharma announced that its BCL2 inhibitor, Mesutoclax (ICP-248), received Breakthrough Therapy Designation from China's NMPA for treating rela...

FDA Grants Orphan Drug Designation to JR-446 for Mucopolysaccharidosis Type IIIB

Regulatory Approvals

08 May 2025

FDA Grants Orphan Drug Designation to JR-446 for Mucopolysaccharidosis Type IIIB

The U.S. Food and Drug Administration (FDA) granted orphan drug designation to JR-446, a drug developed by MEDIPAL HOLDINGS CORPORATION and JCR Pharma...

Viridian Therapeutics' Veligrotug Receives FDA Breakthrough Therapy Designation for Thyroid Eye Disease

Regulatory Approvals

08 May 2025

Viridian Therapeutics' Veligrotug Receives FDA Breakthrough Therapy Designation for Thyroid Eye Disease

Viridian Therapeutics announced that the FDA granted Breakthrough Therapy Designation to veligrotug, its lead drug candidate for treating Thyroid Eye ...

← PrevPage 5 of 5